文献速递前列腺癌

局限性前列腺癌治疗后性、排尿及肠道功能纵向预测的网页工具开发与内部验证

Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation.
PubMed 文献 · Eur Urol · 2020-02-22

基于美国癌症登记处2011-2012年诊断的2563例局限性前列腺癌男性前瞻性队列,利用EPIC-26在治疗前至治疗后5年收集患者报告的性、排尿、肠道及激素功能。构建预测模型并开发网页工具,性功能、尿失禁、尿刺激、肠道及激素领域的偏倚校正R方分别为0.386、0.232、0.183、0.214和0.309,校准优良。工具可基于年龄、种族、PSA、活检分级、基线功能及总体健康问题预测个体化功能结局。

要点

  • 网页工具可基于年龄、种族、PSA、活检分级、基线功能及总体健康预测5年功能结局。
  • 性功能预测模型偏倚校正R方0.386,尿失禁0.232,尿刺激0.183,肠道0.214,激素0.309。
  • 简约模型与综合模型R方差异小,校准优良,支持共享决策。

核心结论

  • 局限性前列腺癌治疗后的功能结局可在诊断时基于年龄、种族、PSA、活检分级、基线功能及总体健康问题预测。

研究设计与样本

  • 前瞻性、基于人群的队列研究,利用美国癌症登记处2563例2011-2012年诊断的局限性前列腺癌男性。
  • 使用26条目EPIC-26问卷收集治疗前至治疗后5年患者报告的排尿、性、肠道及激素功能。

主要发现

  • 预测模型偏倚校正R方:性功能0.386、尿失禁0.232、尿刺激0.183、肠道0.214、激素0.309。
  • 综合模型与简约模型R方差异小,校准优良。
  • 网页工具已开发并可供使用。

关键数值与推荐

  • 预测因子包括年龄、种族、D'Amico分类(简约模型替换为PSA和Gleason评分)、体重指数、EPIC-26基线功能、治疗方式及标准化合并症、总体生活质量、心理社会健康评分。

临床怎么用

  • 提供者与患者可使用该预测工具基于个体特征了解治疗后预期功能结局,以支持共享决策。

局限性

  • 研究为内部验证,未报告外部验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Shared decision making to guide treatment of localized prostate cancer requires delivery of the anticipated quality of life (QOL) outcomes of contemporary treatment options (including radical prostatectomy [RP], intensity-modulated radiation therapy [RT], and active surveillance [AS]). Predicting these QOL outcomes based on personalized features is necessary. OBJECTIVE: To create an easy-to-use tool to predict personalized sexual, urinary, bowel, and hormonal function outcomes after RP, RT, and AS. DESIGN, SETTING, AND PARTICIPANTS: A prospective, population-based cohort study was conducted utilizing US cancer registries of 2563 men diagnosed with localized prostate cancer in 2011-2012. INTERVENTION: Patient-reported urinary, sexual, and bowel function up to 5 yr after treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patient-reported urinary, sexual, bowel, and hormonal function through 5 yr after treatment were collected using the 26-item Expanded Prostate Index Composite (EPIC-26) questionnaire. Comprehensive models to predict domain scores were fit, which included age, race, D'Amico classification, body mass index, EPIC-26 baseline function, treatment, and standardized scores measuring comorbidity, general QOL, and psychosocial health. We reduced these models by removing the instrument scores and replacing D'Amico classification with prostate-specific antigen (PSA) and Gleason score. For the final model, we performed bootstrap internal validation to assess model calibration from which an easy-to-use web-based tool was developed. RESULTS AND LIMITATIONS: The prediction models achieved bias-corrected R-squared values of 0.386, 0.232, 0.183, 0.214, and 0.309 for sexual function, urinary incontinence, urinary irritative, bowel, and hormonal domains, respectively. Differences in R-squared values between the comprehensive and parsimonious models were small in magnitude. Calibration was excellent. The web-based tool is available at https://statez.shinyapps.io/PCDSPred/. CONCLUSIONS: Functional outcomes after treatment for localized prostate cancer can be predicted at the time of diagnosis based on age, race, PSA, biopsy grade, baseline function, and a general question regarding overall health. Providers and patients can use this prediction tool to inform shared decision making. PATIENT SUMMARY: In this report, we studied patient-reported sexual, urinary, hormonal, and bowel function through 5 yr after treatment with radical prostatectomy, radiation therapy, or active surveillance for localized prostate cancer. We developed a web-based predictive tool that can be used to predict one's outcomes after treatment based on age, race, prostate-specific antigen, biopsy grade, pretreatment baseline function, and a general question regarding overall health. We hope both patients and providers can use this tool to better understand expected outcomes after treatment, further enhancing shared decision making between providers and patients.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Laviana AA, Zhao Z, Huang LC, et al. Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. Eur Urol. 2020. PMID: 32098731. doi:10.1016/j.eururo.2020.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。